PDF(Pubmed)
Abstract：
Side effects and low efficacy of current anti-toxoplasmosis therapeutics against encysted bradyzoites necessitate research into alternative safe therapeutic options. The safety, immunostimulatory, and antimicrobial properties of alginate nanoparticle formulation (Alg-NP) highlight its potential as an oral therapy against acute toxoplasmosis. In the current study, Alg-NP was formulated and characterized and then assessed for its anti-Toxoplasma effects using parasitological, ultrastructural, immunological, and histopathological studies. Treatment with Alg-NP significantly prolonged mice survival and reduced the parasite burden in both peritoneal fluid and tissue impression smears. In addition, it altered parasite viability and caused severe tachyzoite deformities as evidenced by ultrastructural studies. Alg-NP induced high levels of serum IFN-γ in infected mice with significant amelioration in histopathological changes in both hepatic and splenic tissue sections. In conclusion, Alg-NP could be considered a promising therapeutic agent against acute murine toxoplasmosis, and owing to its safety, it could potentially be enlisted for human use.
摘要：
目前的抗弓形虫病疗法对封闭的缓生孢子的副作用和低功效需要研究替代的安全治疗选择。安全,免疫刺激,海藻酸盐纳米颗粒制剂（Alg-NP）的抗菌性能突出了其作为口服治疗急性弓形虫病的潜力。在目前的研究中,Alg-NP被配制和表征，然后使用寄生虫评估其抗弓形虫作用，超微结构，免疫学，和组织病理学研究。用Alg-NP治疗可显着延长小鼠的存活率，并减少腹膜液和组织印模涂片中的寄生虫负担。此外,超微结构研究证明，它改变了寄生虫的生存能力并引起了严重的速殖子畸形。Alg-NP在感染的小鼠中诱导高水平的血清IFN-γ，并显着改善了肝和脾组织切片的组织病理学变化。总之,Alg-NP可以被认为是一种有前途的治疗急性小鼠弓形虫病的药物。由于它的安全，它可能会被征召入伍供人类使用。
